LYT-100 in Post-acute COVID-19 Respiratory Disease
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind,
parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in
adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension
(OLE) study for patients who complete Part A.